A PHASE 3, PROSPECTIVE, OPEN-LABEL, MULTISITE, EXTENSION OF PHASE 3 STUDIES TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF SOTICLESTAT AS ADJUNCTIVE THERAPY IN SUBJECTS WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME (ENDYMION 2)

Registry ID

TAK-935-3003

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

TAKEDA DEVELOPMENT CENTER AMERICAS INC

Start date

2023-10-27

Completion date

2026-02-10

Last update

2022-03-22

Conditions

• LENNOX-GASTAUT SYNDROME
• DRAVET SYNDROME

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF LP352 IN THE TREATMENT OF SEIZURES IN CHILDREN AND ADULTS WITH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF LP352 IN THE TREATMENT OF SEIZURES IN CHILDREN AND ADULTS WITH DRAVET SYNDROME
• A 20-WEEK MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EPX-100 (CLEMIZOLE HYDROCHLORIDE) AS ADJUNCTIVE THERAPY IN CHILDREN AND ADULT PARTICIPANTS WITH DRAVET SYNDROME (ARGUS TRIAL)
• CANNABIDIOL IN CHILDREN WITH REFRACTORY EPILEPTIC ENCEPHALOPATHY: A PHASE 1 OPEN LABEL DOSE ESCALATION STUDY

View on source registry